Tuesday, November 30, 2010

US 49th in Life Expectancy but don't tell John Boehner

0 comments
Coming soon to your health insurance plan, especially as the deficit commission plans to shift more costs from employers to workers.
Please Mr Obama, stop caving in on the needs of the people who are your true "boss".  Listen up and stay away from those back room deals with politcos...
Inefficiency Hurts U.S. in Longevity Rankings By NICHOLAS BAKALAR
November 29, 2010


By any measure, the United States spends more on health care than any other nation. Yet according to the World Fact Book (published by the Central Intelligence Agency), it ranks 49th in life expectancy.
Why?
Researchers writing in the November issue of the journal Health Affairs say they know the answer. After citing statistical evidence showing that American patterns of obesity, smoking, traffic accidents and homicide are not the cause of lower life expectancy, they conclude that the problem is the health care system.
Peter A. Muennig and Sherry A. Glied, researchers at the Mailman School of Public Health at Columbia University, compared the performance of the United States and 12 other industrialized nations: Australia, Austria, Belgium, Britain, Canada, France, Germany, Italy, Japan, the Netherlands, Sweden and Switzerland. In addition to health care expenditures in each country, they focused on two other important statistics: 15-year survival for people at 45 years and for those at 65 years.
The researchers say those numbers present an accurate picture of public health because they measure a country’s success in preventing and treating the most common causes of death — cardiovascular disease, stroke and diabetes — which are more likely to occur at these ages. Their data come from the World Health Organization and cover 1975 to 2005.
Life expectancy increased over those years in all 13 countries, and so did health care costs. But the United States had the lowest increase in life expectancy and the highest increase in costs.
In 1975 the United States was close to the average in health care costs, and last in 15-year survival for 45-year-old men. By 2005 its costs had more than tripled, far surpassing increases elsewhere, but the survival number was still last — a little over 90 percent, compared with more than 94 percent for Swedes, Swiss and Australians. For women, it was 94 percent in the United States, versus 97 percent in Switzerland, Australia and Japan.
The numbers for 65-year-olds in 2005 were similar: about 58 percent of American men could be expected to survive 15 years, compared with more than 65 percent of Australians, Japanese and Swiss. While more than 80 percent of 65-year-old women in France, Switzerland, and Japan would survive 15 years, only about 70 percent of American women could be expected to live that long.
In narrowing the blame to the American health care system, the researchers first eliminated several other factors. Obesity and smoking are the most important behavior-related causes of death, but obesity increased more slowly in the United States than in the other countries and smoking declined more rapidly, so neither can explain the differences in survival rates. Homicide and traffic fatality rates have remained steady over time, and social, economic and educational factors do not vary greatly among these countries.
But not all experts agree with this analysis. Samuel Preston, a demographer and a professor of sociology at the University of Pennsylvania, says the analysis is faulty.
“The basic message is correct — that measures of U.S. health, including mortality and morbidity, are very poor in comparison with other countries,” he said. But the Columbia researchers “have no direct evidence about the health care system in this article,” he continued. “Their conclusion is extremely speculative.”
That they did not find smoking at fault, Dr. Preston said, “is mysterious to me, particularly since they show high lung cancer mortality for the U.S.” Dr. Preston has published widely on mortality trends and the effects of smoking.
Dr. Muennig conceded that the study examined only life expectancy and health care spending in the 13 countries, and not the structure or economics of health care. “We did a pretty good job of showing that smoking isn’t the culprit,” he said.
“Smoking and obesity are still major risk factors for an individual’s health,” he said. “But they are sapping life expectancy in all countries. Whereas in the U.S. we have a highly inefficient health system that’s taking away financial resources from other lifesaving programs.” SOURCE
and from UPI, trends in waiting, as the health insurance reform bill waits to go full throttle -

Some insurers switch to cheaper drugs

UPPER NYACK, N.Y., Nov. 30 (UPI) -- Health insurers change as much as 70 percent of medication prescriptions, resulting in adverse reactions among some patients, a U.S. survey indicates.
A survey by the Global Healthy Living Foundation, a non-profit patient advocacy group, found some patients with chronic conditions who responded well to a particular drug relapsed after being switched to a cheaper drug.
"This disturbing finding is not a simple case of switching a brand-name drug for a generic one, a common and generally accepted practice used for many illnesses, and one GHLF supports," Louis Tharp, executive director of the GHLP, says in a statement. "We found that health insurance companies throughout the U.S. switch one brand-name drug for another simply because the switched drug is cheaper -- if the drugs are identical, physicians generally have no objection, the survey found, but national medical groups have said most drugs are not identical and switching can cause adverse reactions and poor recovery rates."
Tharp says his group is working with other advocacy groups, state insurance commissioners, the U.S. Food and Drug Administration and state attorneys general to see what action can be taken to stop the practice.
"Switching is a practice that is starting to get a lot of attention," Tharp says.
"Legislation pending in New York, California and Missouri would outlaw this practice," and, he added, "Louisiana passed a law last year prohibiting it."
No survey details were provided.
Perhaps this abstract from AHRP.org says more, just like the Harvard study that found only 80% or modern medicine actually works...

Medical Errors Contribute to Hospital Deaths -
In 1999, the Institute of Medicine issued a landmark report, To Err is Human, documenting the extraordinary high rate of fatal medical errors at U.S. hospitals: medical errors caused 98,000 deaths and more than a million injuries a year, most being preventable.  

Two major recent analyses of U.S. hospital safety found NO IMPROVEMENT in patient safety.

One study, by a Harvard Medical School team analyzed medical errors at 10 North Carolina hospitals found: "harm to patients was common and the number of incidents did not decrease over time."  For every 100 patients admitted to a hospital, 25 suffered harm requiring medical intervention.

The other study, by the U.S. Inspector General of the DHHS, analyzed 1,000,000 Medicare patients' hospital records documenting that 1 in 7 suffered adverse events during hospitalization in the month of October, 2010.  The IG report calculates the cost of such errors to taxpayers to be several billion dollars a year.
Continue reading →

US 49th in Life Expectancy but don't tell John Boehner

0 comments
Coming soon to your health insurance plan, especially as the deficit commission plans to shift more costs from employers to workers.
Please Mr Obama, stop caving in on the needs of the people who are your true "boss".  Listen up and stay away from those back room deals with politcos...
Inefficiency Hurts U.S. in Longevity Rankings By NICHOLAS BAKALAR
November 29, 2010


By any measure, the United States spends more on health care than any other nation. Yet according to the World Fact Book (published by the Central Intelligence Agency), it ranks 49th in life expectancy.
Why?
Researchers writing in the November issue of the journal Health Affairs say they know the answer. After citing statistical evidence showing that American patterns of obesity, smoking, traffic accidents and homicide are not the cause of lower life expectancy, they conclude that the problem is the health care system.
Peter A. Muennig and Sherry A. Glied, researchers at the Mailman School of Public Health at Columbia University, compared the performance of the United States and 12 other industrialized nations: Australia, Austria, Belgium, Britain, Canada, France, Germany, Italy, Japan, the Netherlands, Sweden and Switzerland. In addition to health care expenditures in each country, they focused on two other important statistics: 15-year survival for people at 45 years and for those at 65 years.
The researchers say those numbers present an accurate picture of public health because they measure a country’s success in preventing and treating the most common causes of death — cardiovascular disease, stroke and diabetes — which are more likely to occur at these ages. Their data come from the World Health Organization and cover 1975 to 2005.
Life expectancy increased over those years in all 13 countries, and so did health care costs. But the United States had the lowest increase in life expectancy and the highest increase in costs.
In 1975 the United States was close to the average in health care costs, and last in 15-year survival for 45-year-old men. By 2005 its costs had more than tripled, far surpassing increases elsewhere, but the survival number was still last — a little over 90 percent, compared with more than 94 percent for Swedes, Swiss and Australians. For women, it was 94 percent in the United States, versus 97 percent in Switzerland, Australia and Japan.
The numbers for 65-year-olds in 2005 were similar: about 58 percent of American men could be expected to survive 15 years, compared with more than 65 percent of Australians, Japanese and Swiss. While more than 80 percent of 65-year-old women in France, Switzerland, and Japan would survive 15 years, only about 70 percent of American women could be expected to live that long.
In narrowing the blame to the American health care system, the researchers first eliminated several other factors. Obesity and smoking are the most important behavior-related causes of death, but obesity increased more slowly in the United States than in the other countries and smoking declined more rapidly, so neither can explain the differences in survival rates. Homicide and traffic fatality rates have remained steady over time, and social, economic and educational factors do not vary greatly among these countries.
But not all experts agree with this analysis. Samuel Preston, a demographer and a professor of sociology at the University of Pennsylvania, says the analysis is faulty.
“The basic message is correct — that measures of U.S. health, including mortality and morbidity, are very poor in comparison with other countries,” he said. But the Columbia researchers “have no direct evidence about the health care system in this article,” he continued. “Their conclusion is extremely speculative.”
That they did not find smoking at fault, Dr. Preston said, “is mysterious to me, particularly since they show high lung cancer mortality for the U.S.” Dr. Preston has published widely on mortality trends and the effects of smoking.
Dr. Muennig conceded that the study examined only life expectancy and health care spending in the 13 countries, and not the structure or economics of health care. “We did a pretty good job of showing that smoking isn’t the culprit,” he said.
“Smoking and obesity are still major risk factors for an individual’s health,” he said. “But they are sapping life expectancy in all countries. Whereas in the U.S. we have a highly inefficient health system that’s taking away financial resources from other lifesaving programs.” SOURCE
and from UPI, trends in waiting, as the health insurance reform bill waits to go full throttle -

Some insurers switch to cheaper drugs

UPPER NYACK, N.Y., Nov. 30 (UPI) -- Health insurers change as much as 70 percent of medication prescriptions, resulting in adverse reactions among some patients, a U.S. survey indicates.
A survey by the Global Healthy Living Foundation, a non-profit patient advocacy group, found some patients with chronic conditions who responded well to a particular drug relapsed after being switched to a cheaper drug.
"This disturbing finding is not a simple case of switching a brand-name drug for a generic one, a common and generally accepted practice used for many illnesses, and one GHLF supports," Louis Tharp, executive director of the GHLP, says in a statement. "We found that health insurance companies throughout the U.S. switch one brand-name drug for another simply because the switched drug is cheaper -- if the drugs are identical, physicians generally have no objection, the survey found, but national medical groups have said most drugs are not identical and switching can cause adverse reactions and poor recovery rates."
Tharp says his group is working with other advocacy groups, state insurance commissioners, the U.S. Food and Drug Administration and state attorneys general to see what action can be taken to stop the practice.
"Switching is a practice that is starting to get a lot of attention," Tharp says.
"Legislation pending in New York, California and Missouri would outlaw this practice," and, he added, "Louisiana passed a law last year prohibiting it."
No survey details were provided.
Perhaps this abstract from AHRP.org says more, just like the Harvard study that found only 80% or modern medicine actually works...

Medical Errors Contribute to Hospital Deaths -
In 1999, the Institute of Medicine issued a landmark report, To Err is Human, documenting the extraordinary high rate of fatal medical errors at U.S. hospitals: medical errors caused 98,000 deaths and more than a million injuries a year, most being preventable.  

Two major recent analyses of U.S. hospital safety found NO IMPROVEMENT in patient safety.

One study, by a Harvard Medical School team analyzed medical errors at 10 North Carolina hospitals found: "harm to patients was common and the number of incidents did not decrease over time."  For every 100 patients admitted to a hospital, 25 suffered harm requiring medical intervention.

The other study, by the U.S. Inspector General of the DHHS, analyzed 1,000,000 Medicare patients' hospital records documenting that 1 in 7 suffered adverse events during hospitalization in the month of October, 2010.  The IG report calculates the cost of such errors to taxpayers to be several billion dollars a year.
Continue reading →

An Interesting Take on How You Can Trust the FDA

0 comments
Most who know me know that I have worked in mental health and psych for many years, albeit, mainly with a keen interest in natural mental health.

I believe nutrition has a very important role in health, physical and mental.  However, with the furor over S510 it does concern me that good, sound nutrition won't be part of the landscape.

And as you can see here in the following three articles, leaving it to the FDA leads us down a very slippery slope.

Looks like more and more no one in Congress or government is doing too much of a good job for the electorate these days.

And outside the issue of risky antidepressant drugs, FDA allows so many more that we have alerted our readers to their dangers for many, many years... 
The antidepressant reboxetine: A headdesk moment in science

Every so often there comes a truly "headdesk" moment in science. A moment where you sit there, stunned by a new finding, and thinking, blankly..."ok, now what?"
For psychiatry and behavioral pharmacology, one of those moments came a few weeks ago with the findings of a meta-analysis published in the British Medical Journal (Eyding et al., 2010). The meta-analysis showed that an antidepressant, reboxetine (marketed by Pfizer in Europe, but not in the US, under the names Edronax, Norebox, Prolift, Solvex, Davedax or Vestra) doesn’t work. Not only does it not work, it REALLY doesn’t work, and it turns out that Pfizer hadn’t published data on the putative antidepressant from 74% of their patients. Some people have reported that the study found that reboxetine was even "possibly harmful," but that’s not quite true. What the study DID find is that reboxetine produced more side effects (noted as "adverse events") than placebo (as might be expected), but with no positive effects at all. While many antidepressants on the market today are not great, most are effective in around 60% of patients, reboxetine turns out to be even worse than that.
SOURCE and complete article
----------------------------------------------------------------------------------------------------------
The next two reports come from the Alliance for Human Research Protection news feed, www.ahrp.org

A letter of complaint by the Project on Government Oversight (POGO) was sent to the director of the National Institutes of Health, documenting $66.8 million in NIH grants over the last five years awarded to a handful of psychiatrists who used ghostwriters for scientific publications. 

The instances in the letter involve ghostwriting by only one company--Scientific Therapeutics Information-- and involve only one drug--GlaxoSmithkline's antidepressant, Paxil.

Duff Wilson of The New York Times reports that previously sealed GlaxoSmithKline documents reveal that a textbook in psychiatry, whose listed authors are  Charles Nemeroff, MD and Alan Schatzberg, MD, was actually ghostwritten by Sally Laden of STI. GSK paid the ghostwriter and the "authors" who penned their names to the book.

The sheer audacity prompted former FDA commissioner, Dr. David Kessler to exclaim: "To ghostwrite an entire textbook is a new level of chutzpah. "I've never heard of that before. It takes your breath away."  Surely that is a
dubious distinction in academic medicine!
and
On November 23, 2010, Terry Vermillion, Director of FDA's Office of Criminal Investigation announced his  retirement next month amid a brewing scandal involving corrupt practices.

The announcement came after complaints by Republicans in Congress who raised concern about his misdirection of the Office's resources: instead of pursuing drug companies and researchers who commit crimes when seeking FDA approval for drugs, OCI pursued drug-abuse cases--which are the purview of the Drug Enforcement Agency.

The issue came to a head when Senator Chuck Grassley sent a complaint to the Acting Comptroller General of the General Accounting Office (GAO) about a "less than stellar" GAO investigative report which whitewashed misconduct at OCI. 

The investigation and the report were compromised by a GAO mole who tipped off someone at the Office of Criminal Investigations.
http://online.wsj.com/public/resources/documents/grassleyletter.pdf   
Continue reading →

An Interesting Take on How You Can Trust the FDA

0 comments
Most who know me know that I have worked in mental health and psych for many years, albeit, mainly with a keen interest in natural mental health.

I believe nutrition has a very important role in health, physical and mental.  However, with the furor over S510 it does concern me that good, sound nutrition won't be part of the landscape.

And as you can see here in the following three articles, leaving it to the FDA leads us down a very slippery slope.

Looks like more and more no one in Congress or government is doing too much of a good job for the electorate these days.

And outside the issue of risky antidepressant drugs, FDA allows so many more that we have alerted our readers to their dangers for many, many years... 
The antidepressant reboxetine: A headdesk moment in science

Every so often there comes a truly "headdesk" moment in science. A moment where you sit there, stunned by a new finding, and thinking, blankly..."ok, now what?"
For psychiatry and behavioral pharmacology, one of those moments came a few weeks ago with the findings of a meta-analysis published in the British Medical Journal (Eyding et al., 2010). The meta-analysis showed that an antidepressant, reboxetine (marketed by Pfizer in Europe, but not in the US, under the names Edronax, Norebox, Prolift, Solvex, Davedax or Vestra) doesn’t work. Not only does it not work, it REALLY doesn’t work, and it turns out that Pfizer hadn’t published data on the putative antidepressant from 74% of their patients. Some people have reported that the study found that reboxetine was even "possibly harmful," but that’s not quite true. What the study DID find is that reboxetine produced more side effects (noted as "adverse events") than placebo (as might be expected), but with no positive effects at all. While many antidepressants on the market today are not great, most are effective in around 60% of patients, reboxetine turns out to be even worse than that.
SOURCE and complete article
----------------------------------------------------------------------------------------------------------
The next two reports come from the Alliance for Human Research Protection news feed, www.ahrp.org

A letter of complaint by the Project on Government Oversight (POGO) was sent to the director of the National Institutes of Health, documenting $66.8 million in NIH grants over the last five years awarded to a handful of psychiatrists who used ghostwriters for scientific publications. 

The instances in the letter involve ghostwriting by only one company--Scientific Therapeutics Information-- and involve only one drug--GlaxoSmithkline's antidepressant, Paxil.

Duff Wilson of The New York Times reports that previously sealed GlaxoSmithKline documents reveal that a textbook in psychiatry, whose listed authors are  Charles Nemeroff, MD and Alan Schatzberg, MD, was actually ghostwritten by Sally Laden of STI. GSK paid the ghostwriter and the "authors" who penned their names to the book.

The sheer audacity prompted former FDA commissioner, Dr. David Kessler to exclaim: "To ghostwrite an entire textbook is a new level of chutzpah. "I've never heard of that before. It takes your breath away."  Surely that is a
dubious distinction in academic medicine!
and
On November 23, 2010, Terry Vermillion, Director of FDA's Office of Criminal Investigation announced his  retirement next month amid a brewing scandal involving corrupt practices.

The announcement came after complaints by Republicans in Congress who raised concern about his misdirection of the Office's resources: instead of pursuing drug companies and researchers who commit crimes when seeking FDA approval for drugs, OCI pursued drug-abuse cases--which are the purview of the Drug Enforcement Agency.

The issue came to a head when Senator Chuck Grassley sent a complaint to the Acting Comptroller General of the General Accounting Office (GAO) about a "less than stellar" GAO investigative report which whitewashed misconduct at OCI. 

The investigation and the report were compromised by a GAO mole who tipped off someone at the Office of Criminal Investigations.
http://online.wsj.com/public/resources/documents/grassleyletter.pdf   
Continue reading →

More on Low Cholesterol Dangers

0 comments
Several years ago I started a thread about the risk of having too low levels of cholesterol, following on all of the work I had been trying to do over many years to educate people about the risk of cholesterol lowering drugs.

One sad situation is that of a friend who with his MS doctor agreed to using these drugs.  He ended up in a wheel chair.

It is just all hit or miss in prescribing these days.  More " miss", and probably why incoming House leader Boehner thinks we have the best health care in the world here in the US. Consistent ranking in the high 30s and 40s tells otherwise.  But I guess we aren't on the payola train like most members of Congress these days.

I happened to see this link so I thought I'd add it in to the 30+ posts on the low cholesterol and related "health matters" -

The Overlooked Health Risks of Very Low Cholesterol

Selected posts from Natural Health News
Natural Health News: Low Cholesterol Risks
Nov 13, 2008
While most hear about how high cholesterol is so bad and how many risky drugs you need, often you don't hear that low cholesterol can impair your immune function or defer review of other more risky markers. Triglycerides included.
Feb 23, 2008
Some studies have linked low cholesterol levels to higher death rates from cancer in general, Dr. Kouichi Asano, of Kyushu University, Fukuoka, and colleagues explain in the International Journal of Cancer. "With respect to gastric ...
Dec 23, 2008
This new study, with a reasonable sample size, unlike most studies I review, raises concern over low cholesterol levels. As someone who has been a skeptic on the cholesterol drug mania for so very many years I am pleased to see this ...
Aug 21, 2008
But wait a minute, even if this were true, how about if lower levels of cholesterol actually increased our risk of other important conditions? Might an increased risk of, say, cancer, offset any apparent advantages of low cholesterol ...

Continue reading →

More on Low Cholesterol Dangers

0 comments
Several years ago I started a thread about the risk of having too low levels of cholesterol, following on all of the work I had been trying to do over many years to educate people about the risk of cholesterol lowering drugs.

One sad situation is that of a friend who with his MS doctor agreed to using these drugs.  He ended up in a wheel chair.

It is just all hit or miss in prescribing these days.  More " miss", and probably why incoming House leader Boehner thinks we have the best health care in the world here in the US. Consistent ranking in the high 30s and 40s tells otherwise.  But I guess we aren't on the payola train like most members of Congress these days.

I happened to see this link so I thought I'd add it in to the 30+ posts on the low cholesterol and related "health matters" -

The Overlooked Health Risks of Very Low Cholesterol

Selected posts from Natural Health News
Natural Health News: Low Cholesterol Risks
Nov 13, 2008
While most hear about how high cholesterol is so bad and how many risky drugs you need, often you don't hear that low cholesterol can impair your immune function or defer review of other more risky markers. Triglycerides included.
Feb 23, 2008
Some studies have linked low cholesterol levels to higher death rates from cancer in general, Dr. Kouichi Asano, of Kyushu University, Fukuoka, and colleagues explain in the International Journal of Cancer. "With respect to gastric ...
Dec 23, 2008
This new study, with a reasonable sample size, unlike most studies I review, raises concern over low cholesterol levels. As someone who has been a skeptic on the cholesterol drug mania for so very many years I am pleased to see this ...
Aug 21, 2008
But wait a minute, even if this were true, how about if lower levels of cholesterol actually increased our risk of other important conditions? Might an increased risk of, say, cancer, offset any apparent advantages of low cholesterol ...

Continue reading →

Senate passes food-safety legislation -

0 comments
Senate passes food-safety legislation - latimes.com

Get more information here 

UPDATE: The bill, with language that is substantially different from its original version, passed the Senate on Tuesday morning by a vote of 73 to 25. 

See how  senate members voted
http://www.senate.gov/legislative/LIS/roll_call_lists/roll_call_vote_cfm.cfm?congress=111&session=2&vote=00257
The legislation—the FDA Food Safety Modernization Act (S. 510)—was intended to get the FDA to crack down on unsafe foods before they harm people rather than after outbreaks occur. This was especially controversial because of a number of provisions that would have created a litany of unintended regulatory consequences for small organic farms and supplement manufacturers. The bill is better now than its earlier version despite push back from anti-health-supplement proponents and the processed food industry. 

The work of a diverse and dedicated coalition and a few members of Congress helped change the bill for the better.

Here are some of the changes that grass roots ans organizational allies have made to the Food Safety bill:
  • Excluded excessive punishment.
S. 510 will not include the obscene ten-year jail sentences for food and supplement manufacturers who violate complicated FDA rules. That language was specifically designed to target supplement manufacturers while leaving pharmaceutical drug and medical device companies untouched.
  • Resisted international harmonization of food and health supplement policy.
Language in the bill was modified to prevent the US from harmonizing to  international food and supplement rules as in Europe, where attempts are being made to regulate away natural health.
  • Excluded small farmers from burdensome regulation.
Some small-farm and organic food advocates warned that the legislation would destroy their industry under a mountain of paperwork. An amendment from Sen. Jon Tester (D-MT), which exempts producers with less than $500,000 a year in sales who sell most of their food locally was included in the Senate version. Many organizations fought tirelessly to protect the burgeoning local healthy food movement from unwarranted federal regulation, and from the processed food companies that are increasingly nervous about competition. Thirty processed food organizations like the American Frozen Food Institute and the Corn Refiners Association sent a letter to the Senate arguing that a local produce stand should face the same regulatory hurdles as their industrial-scale processed food operations.

The House of Representatives agreed to adopt this Senate version of the bill instead of the 2009 House version. 
The bill now continues to have a lot wrong with it. 
There will be opportunities to change more through the rule making process as the FDA adds more regulation.

Information supplied by ANH may be included in this update.
Continue reading →

Senate passes food-safety legislation -

0 comments
Senate passes food-safety legislation - latimes.com

Get more information here 

UPDATE: The bill, with language that is substantially different from its original version, passed the Senate on Tuesday morning by a vote of 73 to 25. 

See how  senate members voted
http://www.senate.gov/legislative/LIS/roll_call_lists/roll_call_vote_cfm.cfm?congress=111&session=2&vote=00257
The legislation—the FDA Food Safety Modernization Act (S. 510)—was intended to get the FDA to crack down on unsafe foods before they harm people rather than after outbreaks occur. This was especially controversial because of a number of provisions that would have created a litany of unintended regulatory consequences for small organic farms and supplement manufacturers. The bill is better now than its earlier version despite push back from anti-health-supplement proponents and the processed food industry. 

The work of a diverse and dedicated coalition and a few members of Congress helped change the bill for the better.

Here are some of the changes that grass roots ans organizational allies have made to the Food Safety bill:
  • Excluded excessive punishment.
S. 510 will not include the obscene ten-year jail sentences for food and supplement manufacturers who violate complicated FDA rules. That language was specifically designed to target supplement manufacturers while leaving pharmaceutical drug and medical device companies untouched.
  • Resisted international harmonization of food and health supplement policy.
Language in the bill was modified to prevent the US from harmonizing to  international food and supplement rules as in Europe, where attempts are being made to regulate away natural health.
  • Excluded small farmers from burdensome regulation.
Some small-farm and organic food advocates warned that the legislation would destroy their industry under a mountain of paperwork. An amendment from Sen. Jon Tester (D-MT), which exempts producers with less than $500,000 a year in sales who sell most of their food locally was included in the Senate version. Many organizations fought tirelessly to protect the burgeoning local healthy food movement from unwarranted federal regulation, and from the processed food companies that are increasingly nervous about competition. Thirty processed food organizations like the American Frozen Food Institute and the Corn Refiners Association sent a letter to the Senate arguing that a local produce stand should face the same regulatory hurdles as their industrial-scale processed food operations.

The House of Representatives agreed to adopt this Senate version of the bill instead of the 2009 House version. 
The bill now continues to have a lot wrong with it. 
There will be opportunities to change more through the rule making process as the FDA adds more regulation.

Information supplied by ANH may be included in this update.
Continue reading →
Monday, November 29, 2010

Scientific Foundation for Homeopathy Discovered

0 comments
A NOBEL laureate who discovered the link between HIV and AIDS has suggested there could be a firm scientific foundation for homeopathy.

French virologist Luc Montagnier stunned his colleagues at a prestigious international conference when he presented a new method for detecting viral infections that bore close parallels to the basic tenets of homeopathy.
http://college-of-practical-homeopathy.com/scientific-basis-of-homeopathy.html
Continue reading →

Scientific Foundation for Homeopathy Discovered

0 comments
A NOBEL laureate who discovered the link between HIV and AIDS has suggested there could be a firm scientific foundation for homeopathy.

French virologist Luc Montagnier stunned his colleagues at a prestigious international conference when he presented a new method for detecting viral infections that bore close parallels to the basic tenets of homeopathy.
http://college-of-practical-homeopathy.com/scientific-basis-of-homeopathy.html
Continue reading →

S 510 Status Report - Food Safety Bill

0 comments
UPDATE:  This bill has now passed in both the house and senate.  Let Obama know you don't want it signed.

Nov. 29, 2010, from Weston A Price Foundation

The final vote on S.510, the Food safety Modernization Act, is scheduled for this evening (Monday, November 29). The first step will be a cloture vote to allow the Managers Package version of the bill to proceed, which will require 60 votes. Four amendments will then be debated, followed by a final vote on the bill.

As it currently stands, the Managers Package of the bill includes the Tester-Hagan amendment. For many months, we have been pushing for this amendment to be included in the bill to carve out a sphere of protection for small-scale, direct marketing producers. The version of the Tester-Hagan amendment that is included in the bill exempts producers grossing under $500,000 (adjusted for inflation) and selling more than half of their products directly to qualified end users from the HACCP-type requirements and the produce safety standards. Qualified end users means individual consumers (with no geographic limitation), or restaurants and retail food establishments that are EITHER located in the same state OR within 275 miles of the producer. While complex, this amendment effectively carves out small-scale producers who are selling in-state or to local foodsheds from two of the most burdensome provisions of the bill.

At the same time, we dont think S.510 is a good bill even with the amendment. It increases FDAs power, which will undoubtedly lead to even more battles between FDA and local food producers and consumers. FDA has abused the powers it already has, and that will almost certainly continue, with or without this bill.

We also know that Big Agribusiness is NOT happy with the inclusion of the Tester-Hagan amendment in the bill. Groups such as the Produce Marketing Association and the Western Growers Association are busy lobbying the Senate to try to have the amendment pulled back out.

As bad as the bill is now, it would be even worse without the amendment!

Different people and organizations have different views, so you may get conflicting advice. Our belief is that the bill will most likely pass the Senate, and that it is critical to ensure that the protections of the Tester-Hagan amendment are not lost in last-minute backroom deals.

WHATS NEXT?

If S510 passes the Senate this week, there is still more to come. First, the bill will go to the House of Representatives. Rather than try to reconcile the bill with the House version (HR 2749), the House leadership has agreed to put S510 to a vote on the floor of the House. Because time is running out for this Congress, any changes by the House would almost certainly kill the bill. If the House passes S510, it then goes to the President.

Second, next year, Congress will face the question of appropriating money to implement the new laws and regulations. S510 authorizes, but does not appropriate, monies for the FDA-expanded regulation of domestic and imported conventional food producers, distributors, and retailers, and the hiring of more FDA bureaucrats. To carry out all of the new rules and FDA authorities, Congress will have to approve $1.4 billion of new spending or cut other programs accordingly, based on the CBO estimates. This gives us a chance to affect the level of funding and how the money can be spent.

Third, FDA will start the rulemaking process. The agency will almost certainly try to marginalize the role of local foods producers and consumers in the process. We will have to take action to ensure that our concerns are on the record and that elected officials in Congress are also involved to try to rein in the agency from overstepping its bounds.

ACTION TO TAKE:

Call your Senators and ask to speak to the staffer who handles food safety issues. Urge them to, at a minimum, stand firm on including the Tester-Hagan amendment in the bill. Explain to them that local food producers and consumers already face problems because of FDA, and we are worried about what FDA will do with expanded powers. And then look beyond the bill, and ask them to take action to protect local food producers through the appropriations process and through oversight of the agency. Tell them that you will hold your Senators accountable for what FDA does, and that their job does not end with this bill.

If you get their voice mail, leave a message: My name is ____, and I am a constituent who is concerned about the expanded authority that FDA would have under S510, the food safety bill. I urge Senator _____ to, at a minimum, ensure that the Tester-Hagan amendment stays in the bill. The FDA has a track record of abusing its authority to go after small-scale producers, while turning a blind eye to the many problems caused by large industrial producers. With or without S510, I urge my Senator to take steps to rein in the FDAs abuses. I would like to talk with you more about this, please call me back at ________.

CONTACT INFO:

You can call the Capitol Switchboard at 202-224-3121 and ask to be connected to your Senators offices. You can also find your Senators contact information online at http://www.senate.gov/general/contact_information/senators_cfm.cfm If their phone line is busy, you can use their web form to contact them or fax a short note.

OTHER NOTES OF INTEREST

During the last several months, we have also asked you to call on two other amendments to the bill: to support an amendment to ban BPA and to oppose an amendment to add criminal penalties. Senator Feinstein chose to withdraw her amendment to ban BPA in the face of industry opposition. Senator Leahy's amendment to add criminal penalties appears to be dead, although we will continue to watch for it.
Continue reading →

S 510 Status Report - Food Safety Bill

0 comments
UPDATE:  This bill has now passed in both the house and senate.  Let Obama know you don't want it signed.

Nov. 29, 2010, from Weston A Price Foundation

The final vote on S.510, the Food safety Modernization Act, is scheduled for this evening (Monday, November 29). The first step will be a cloture vote to allow the Managers Package version of the bill to proceed, which will require 60 votes. Four amendments will then be debated, followed by a final vote on the bill.

As it currently stands, the Managers Package of the bill includes the Tester-Hagan amendment. For many months, we have been pushing for this amendment to be included in the bill to carve out a sphere of protection for small-scale, direct marketing producers. The version of the Tester-Hagan amendment that is included in the bill exempts producers grossing under $500,000 (adjusted for inflation) and selling more than half of their products directly to qualified end users from the HACCP-type requirements and the produce safety standards. Qualified end users means individual consumers (with no geographic limitation), or restaurants and retail food establishments that are EITHER located in the same state OR within 275 miles of the producer. While complex, this amendment effectively carves out small-scale producers who are selling in-state or to local foodsheds from two of the most burdensome provisions of the bill.

At the same time, we dont think S.510 is a good bill even with the amendment. It increases FDAs power, which will undoubtedly lead to even more battles between FDA and local food producers and consumers. FDA has abused the powers it already has, and that will almost certainly continue, with or without this bill.

We also know that Big Agribusiness is NOT happy with the inclusion of the Tester-Hagan amendment in the bill. Groups such as the Produce Marketing Association and the Western Growers Association are busy lobbying the Senate to try to have the amendment pulled back out.

As bad as the bill is now, it would be even worse without the amendment!

Different people and organizations have different views, so you may get conflicting advice. Our belief is that the bill will most likely pass the Senate, and that it is critical to ensure that the protections of the Tester-Hagan amendment are not lost in last-minute backroom deals.

WHATS NEXT?

If S510 passes the Senate this week, there is still more to come. First, the bill will go to the House of Representatives. Rather than try to reconcile the bill with the House version (HR 2749), the House leadership has agreed to put S510 to a vote on the floor of the House. Because time is running out for this Congress, any changes by the House would almost certainly kill the bill. If the House passes S510, it then goes to the President.

Second, next year, Congress will face the question of appropriating money to implement the new laws and regulations. S510 authorizes, but does not appropriate, monies for the FDA-expanded regulation of domestic and imported conventional food producers, distributors, and retailers, and the hiring of more FDA bureaucrats. To carry out all of the new rules and FDA authorities, Congress will have to approve $1.4 billion of new spending or cut other programs accordingly, based on the CBO estimates. This gives us a chance to affect the level of funding and how the money can be spent.

Third, FDA will start the rulemaking process. The agency will almost certainly try to marginalize the role of local foods producers and consumers in the process. We will have to take action to ensure that our concerns are on the record and that elected officials in Congress are also involved to try to rein in the agency from overstepping its bounds.

ACTION TO TAKE:

Call your Senators and ask to speak to the staffer who handles food safety issues. Urge them to, at a minimum, stand firm on including the Tester-Hagan amendment in the bill. Explain to them that local food producers and consumers already face problems because of FDA, and we are worried about what FDA will do with expanded powers. And then look beyond the bill, and ask them to take action to protect local food producers through the appropriations process and through oversight of the agency. Tell them that you will hold your Senators accountable for what FDA does, and that their job does not end with this bill.

If you get their voice mail, leave a message: My name is ____, and I am a constituent who is concerned about the expanded authority that FDA would have under S510, the food safety bill. I urge Senator _____ to, at a minimum, ensure that the Tester-Hagan amendment stays in the bill. The FDA has a track record of abusing its authority to go after small-scale producers, while turning a blind eye to the many problems caused by large industrial producers. With or without S510, I urge my Senator to take steps to rein in the FDAs abuses. I would like to talk with you more about this, please call me back at ________.

CONTACT INFO:

You can call the Capitol Switchboard at 202-224-3121 and ask to be connected to your Senators offices. You can also find your Senators contact information online at http://www.senate.gov/general/contact_information/senators_cfm.cfm If their phone line is busy, you can use their web form to contact them or fax a short note.

OTHER NOTES OF INTEREST

During the last several months, we have also asked you to call on two other amendments to the bill: to support an amendment to ban BPA and to oppose an amendment to add criminal penalties. Senator Feinstein chose to withdraw her amendment to ban BPA in the face of industry opposition. Senator Leahy's amendment to add criminal penalties appears to be dead, although we will continue to watch for it.
Continue reading →
Sunday, November 28, 2010

Low Dose Electromagnetic Radiation Depletes Key Nutrients

0 comments
For years I have been alerting skeptics to the fact that non-ionizing radiation indeed has a negative impact, and it can take many forms.

This report is enlightening because it looks at important nutrients and the impact on health.

If you're a consumer of EMF in its many forms, you might wish to look too.

Researchers found these key nutrients to be affected -
Calcium is essential for proper bone formation and teeth, as well as certain hormones and muscle contraction. A deficiency of calcium leads to muscle cramps, eye twitching, sleep disorders, and bone disorders like osteoporosis.

Magnesium deficiency has been linked to heart arrhythmias, visual deficiency, anxiety, confusion. agitation, restless leg syndrome (RLS), sleep disorders, irritability, nausea and vomiting, low blood pressure, muscle spasms, and seizures.

Zinc is required for normal immune function, fertility, and protein synthesis. Insufficient zinc can lead to sleep disorders, behavioral problems, diarrhea, skin rashes, hair loss, hyperactivity, allergies, bowel disease, and reduced fertility.
Ulku R, Akdag MZ, Erdogan S, Akkus Z, Dasdag S.  Extremely Low-Frequency Magnetic Field Decreased Calcium, Zinc and Magnesium Levels in Costa of Rat. Biol Trace Elem Res. 2010 Sep 25. [Epub ahead of print]

SOURCE
Continue reading →

Labels